wegovy novo nordisk - Search News

News

Wegovy maker Novo Nordisk warns of layoffs

Wegovy maker Novo Nordisk warns of layoffs as competition grows

Novo Nordisk’s outgoing CEO, Lars Fruergaard Jorgensen, has warned that layoffs at the Danish pharmaceutical giant could be unavoidable as competition heats up against its blockbuster obesity drug Wegovy amid rising pressure from rival Eli Lilly.

Reuters on MSN · 3d

Novo Nordisk CEO warns of layoffs as Wegovy challenge heats up

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could face layoffs as it battles rising pressure from main U.S. rival Eli Lilly ,

The Economic Times on MSN · 3d

Wegovy maker Novo Nordisk to reduce costs after $95 billion stock loss

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk said on Wednesday it will sharpen its commercial focus and reduce costs, after a major profit warning and new CEO announcement last week wiped some $95 billion of value from the company's stock.

2don MSN

Cash pay is 'going to constitute a major part of the Wegovy business': Novo Nordisk CFO

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

2don MSN

Novo Nordisk’s Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...

pharmaphorum3d

Novo Nordisk weakens again on interim results readout

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...

Pharmaceutical Technology on MSN3d

Novo Nordisk files 14 new lawsuits against unapproved semaglutide drugs

Novo Nordisk has announced the filing of 14 new lawsuits against the sale of unapproved compounded drugs claiming to contain semaglutide.

Novo Nordisk calls for US import ban on key ingredient for obesity drug copycats

Novo Nordisk has called on the US regulator to ban imports of a key ingredient used to make copycat versions of its obesity and diabetes drugs, as the Danish drugmaker loses market share to the ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results